Compounds that obstruct the “landing gear” of a range of harmful viruses can successfully protect against infection by the virus that causes COVID-19, a study led by Dana-Farber Cancer Institute scientists shows. Based on the findings, researchers have launched a human clinical trial of one such compound made by chemically stabilizing a key coronavirus peptide.

The diagnostic, which requires only a simple urine test to read the results, could make lung cancer screening more accessible worldwide.

Medtronic (NYSE: MDT)+
announced today that it received CE mark approval for its next-generation Micra AV2 and Micra VR2 miniature, leadless pacemakers.

Imagine electrostatic materials that function even with extremely weak ultrasound, heralding the era of permanent implantable electronic devices in biomedicine.

iRhythm Technologies (Nasdaq: IRTC)+
announced today that it received CE mark for its Zio system and its supporting Zeus AI algorithm.